טוען...
Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib
Encorafenib/binimetinib is a new combination BRAF/MEK inhibitor used in the treatment of advanced or metastatic BRAFV600-mutant melanoma. Though generally tolerated well, mild to moderate aminotransferase elevations are common. However, significant liver injury has not been demonstrated in the liter...
שמור ב:
| הוצא לאור ב: | Case Rep Oncol Med |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Hindawi
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6800898/ https://ncbi.nlm.nih.gov/pubmed/31687241 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/3051945 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|